Login to Your Account

Shanghai’s EOC Pharma takes a market-led approach to oncology

By Shannon Ellis
Staff Writer

Thursday, January 25, 2018

SHANGHAI – EOC Pharmaceutical Group, a specialty pharma with seven cancer assets in its pipeline, has started with the end in mind – not just getting its drugs approved by the CFDA but having them be commercially successful as well.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription